Key points from article :
Longeveron announced positive results from its Phase 2a CLEAR MIND trial of Lomecel-B for the treatment of mild Alzheimer’s.
“...results provide important validation of both the safety and therapeutic potential of Lomecel-B,” - Wa’el Hashad, CEO of Longeveron.
It has anti-inflammatory and regenerative properties via medicinal signaling cells (MSCs).
No serious safety issues, with one SAE per dosage group and none on placebo.
Lomecel-B at low dose and pooled groups improved Composite Alzheimer's Disease Score (CADS) vs. placebo.
Statistically significant slowing of disease progression in hippocampal volume at low dose.
Other doses demonstrated slowing/prevention of disease worsening relative to placebo.
Encouraging results pave the way for Phase 2b trial with more patients.
